Public Employees Retirement System of Ohio Has $4.86 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Public Employees Retirement System of Ohio lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 9.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,113 shares of the biotechnology company’s stock after selling 6,819 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in BioMarin Pharmaceutical were worth $4,858,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMRN. AGF Management Ltd. bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth $2,563,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth approximately $5,627,000. Teachers Retirement System of The State of Kentucky lifted its stake in shares of BioMarin Pharmaceutical by 17.4% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock valued at $15,990,000 after buying an additional 28,837 shares in the last quarter. E Fund Management Co. Ltd. lifted its position in BioMarin Pharmaceutical by 167.4% in the 2nd quarter. E Fund Management Co. Ltd. now owns 13,480 shares of the biotechnology company’s stock valued at $1,110,000 after acquiring an additional 8,438 shares in the last quarter. Finally, EULAV Asset Management lifted its holdings in shares of BioMarin Pharmaceutical by 12.9% in the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock valued at $9,208,000 after purchasing an additional 15,000 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BMRN shares. UBS Group raised their price target on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wedbush upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research note on Monday, November 4th. Barclays cut their price objective on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating for the company in a report on Friday, October 4th. Sanford C. Bernstein reduced their target price on BioMarin Pharmaceutical from $116.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, September 17th. Finally, Wolfe Research assumed coverage on shares of BioMarin Pharmaceutical in a research report on Friday, November 15th. They set an “outperform” rating and a $95.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.20.

BioMarin Pharmaceutical Trading Down 0.4 %

Shares of BMRN stock opened at $66.01 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The business has a 50-day moving average of $66.97 and a 200 day moving average of $77.14. The stock has a market capitalization of $12.58 billion, a PE ratio of 39.53, a P/E/G ratio of 0.65 and a beta of 0.29. BioMarin Pharmaceutical Inc. has a 1-year low of $61.15 and a 1-year high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The firm had revenue of $746.00 million during the quarter, compared to analysts’ expectations of $703.37 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. BioMarin Pharmaceutical’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.26 EPS. As a group, sell-side analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.49 earnings per share for the current year.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total transaction of $350,300.86. Following the completion of the transaction, the executive vice president now owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.